A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS
and pharmacodynamic effects of CST-103 co-administered with CST-107 in 4 subject populations
with Neurodegenerative Disorders.